Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: dmkst1 who wrote (1051)	6/15/1999 11:31:00 PM
From: Walkingshadow	Respond to of 1686

Harold-- There are many effective medications (both oral and IV) already in use for CHF, and more on the way. The advantage of Adentri, I gather, is that it is less likely to cause renal failure, as sometimes results from overly-aggressive diuresis, and it is also less likely to cause electrolyte imbalances (notably, hypokalemia, but also hyponatremia). This is certainly a nice characteristic, but these things are not, in competent hands, a significant problem in most cases of chronic CHF, and probably of even less concern in acute CHF. This is not to suggest that Adentri will have no role; only that it's role will likely be limited, that the advantages offered will not make this a revolutionary advance in this area, and that therefore pricing power will be limited (and with that, less net profit), particularly given the fiscal constraints of managed care and the host of options for treating CHF currently available and being developed. Walkingshadow